Ignite Creation Date:
2025-12-24 @ 1:51 PM
Ignite Modification Date:
2026-01-24 @ 9:04 PM
Study NCT ID:
NCT04426695
Status:
COMPLETED
Last Update Posted:
2023-01-27
First Post:
2020-06-08
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for Hospitalized Adult Patients With COVID-19
Sponsor:
Regeneron Pharmaceuticals
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | COVID-19 | View |